{"title":"补充维生素d对BioNTech、辉瑞疫苗副作用和COVID-19阳性个体免疫球蛋白G对SARS-CoV-2反应的影响:一项随机对照试验","authors":"Hawal Lateef Fateh, Goran Kareem, Shahab Rezaeian, Jalal Moludi, Negin Kamari","doi":"10.7762/cnr.2023.12.4.269","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vitamin D participates in the biological function of the innate and adaptive immune system and inflammation. We aim to specify the effectiveness of the vitamin D supplementation on the side effects BioNTech, Pfizer vaccination, and immunoglobulin G response against severe acute respiratory syndrome coronavirus 2 in subjects tested positive for coronavirus disease 2019 (COVID-19).</p><p><strong>Methods: </strong>In this multi-center randomized clinical trial, 498 people tested positive for COVID-19 were divided into 2 groups, receiving vitamin D capsules or a placebo (1 capsule daily, each containing 600 IU of vitamin D) over 14-16 weeks. Anthropometric indices and biochemical parameters were measured before and after the second dose of vaccination.</p><p><strong>Result: </strong>Fourteen to 16 weeks after supplementation, the intervention group had an immunoglobulin G (IgG) increase of 10.89 ± 1.2 g/L, while the control group had 8.89 ± 1.3 g/L, and the difference was significant between both groups (p = 0.001). After the second dose of vaccination, the supplement group significantly increased their 25-hydroxy vitamin D from initially 28.73 ± 15.6 ng/mL and increased to 46.48 ± 27.2 ng/mL, and the difference between them was significant. Those with a higher body mass index (BMI) had the most of symptoms, and the difference of side effects according to BMI level was significantly different. In 8 weeks after supplementation obese participants had the lowest IgG levels than overweight or normal subjects. The proportion of all types of side effects on the second dose was significantly diminished compared with the first dose in the intervention group.</p><p><strong>Conclusion: </strong>Supplementation of 600 IU of vitamin D3 can reduce post-vaccination side effects and increase IgG levels in participants who received BioNTech, Pfizer vaccine.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05851313.</p>","PeriodicalId":72617,"journal":{"name":"Clinical nutrition research","volume":"12 4","pages":"269-282"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641329/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Effect of Vit-D Supplementation on the Side Effect of BioNTech, Pfizer Vaccination and Immunoglobulin G Response Against SARS-CoV-2 in the Individuals Tested Positive for COVID-19: A Randomized Control Trial.\",\"authors\":\"Hawal Lateef Fateh, Goran Kareem, Shahab Rezaeian, Jalal Moludi, Negin Kamari\",\"doi\":\"10.7762/cnr.2023.12.4.269\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Vitamin D participates in the biological function of the innate and adaptive immune system and inflammation. We aim to specify the effectiveness of the vitamin D supplementation on the side effects BioNTech, Pfizer vaccination, and immunoglobulin G response against severe acute respiratory syndrome coronavirus 2 in subjects tested positive for coronavirus disease 2019 (COVID-19).</p><p><strong>Methods: </strong>In this multi-center randomized clinical trial, 498 people tested positive for COVID-19 were divided into 2 groups, receiving vitamin D capsules or a placebo (1 capsule daily, each containing 600 IU of vitamin D) over 14-16 weeks. Anthropometric indices and biochemical parameters were measured before and after the second dose of vaccination.</p><p><strong>Result: </strong>Fourteen to 16 weeks after supplementation, the intervention group had an immunoglobulin G (IgG) increase of 10.89 ± 1.2 g/L, while the control group had 8.89 ± 1.3 g/L, and the difference was significant between both groups (p = 0.001). After the second dose of vaccination, the supplement group significantly increased their 25-hydroxy vitamin D from initially 28.73 ± 15.6 ng/mL and increased to 46.48 ± 27.2 ng/mL, and the difference between them was significant. Those with a higher body mass index (BMI) had the most of symptoms, and the difference of side effects according to BMI level was significantly different. In 8 weeks after supplementation obese participants had the lowest IgG levels than overweight or normal subjects. The proportion of all types of side effects on the second dose was significantly diminished compared with the first dose in the intervention group.</p><p><strong>Conclusion: </strong>Supplementation of 600 IU of vitamin D3 can reduce post-vaccination side effects and increase IgG levels in participants who received BioNTech, Pfizer vaccine.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05851313.</p>\",\"PeriodicalId\":72617,\"journal\":{\"name\":\"Clinical nutrition research\",\"volume\":\"12 4\",\"pages\":\"269-282\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641329/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical nutrition research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7762/cnr.2023.12.4.269\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nutrition research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7762/cnr.2023.12.4.269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:维生素D参与先天免疫系统和适应性免疫系统以及炎症的生物学功能。我们的目标是明确维生素D补充剂对BioNTech、辉瑞疫苗接种和免疫球蛋白G对2019冠状病毒病(COVID-19)检测阳性受试者的副作用的有效性。方法:在这项多中心随机临床试验中，498名COVID-19检测呈阳性的人被分为两组，在14-16周内服用维生素D胶囊或安慰剂(每天1粒，每粒含600 IU维生素D)。测定第二次接种前后的人体测量指标和生化指标。结果:补充后14 ~ 16周，干预组免疫球蛋白G (IgG)升高10.89±1.2 G /L，对照组升高8.89±1.3 G /L，两组比较差异有统计学意义(p = 0.001)。第二次接种后，补剂组25-羟基维生素D含量由最初的28.73±15.6 ng/mL显著提高至46.48±27.2 ng/mL，两者差异显著。体重指数(BMI)高的患者出现的症状最多，不同BMI水平的副作用差异也有显著性差异。在补充后的8周内，肥胖参与者的IgG水平低于超重或正常受试者。与第一次给药相比，干预组第二次给药时各种不良反应的比例明显降低。结论:在接受BioNTech、Pfizer疫苗的受试者中，补充600 IU维生素D3可减少疫苗接种后的副作用并提高IgG水平。试验注册:ClinicalTrials.gov标识符:NCT05851313。
The Effect of Vit-D Supplementation on the Side Effect of BioNTech, Pfizer Vaccination and Immunoglobulin G Response Against SARS-CoV-2 in the Individuals Tested Positive for COVID-19: A Randomized Control Trial.
Background: Vitamin D participates in the biological function of the innate and adaptive immune system and inflammation. We aim to specify the effectiveness of the vitamin D supplementation on the side effects BioNTech, Pfizer vaccination, and immunoglobulin G response against severe acute respiratory syndrome coronavirus 2 in subjects tested positive for coronavirus disease 2019 (COVID-19).
Methods: In this multi-center randomized clinical trial, 498 people tested positive for COVID-19 were divided into 2 groups, receiving vitamin D capsules or a placebo (1 capsule daily, each containing 600 IU of vitamin D) over 14-16 weeks. Anthropometric indices and biochemical parameters were measured before and after the second dose of vaccination.
Result: Fourteen to 16 weeks after supplementation, the intervention group had an immunoglobulin G (IgG) increase of 10.89 ± 1.2 g/L, while the control group had 8.89 ± 1.3 g/L, and the difference was significant between both groups (p = 0.001). After the second dose of vaccination, the supplement group significantly increased their 25-hydroxy vitamin D from initially 28.73 ± 15.6 ng/mL and increased to 46.48 ± 27.2 ng/mL, and the difference between them was significant. Those with a higher body mass index (BMI) had the most of symptoms, and the difference of side effects according to BMI level was significantly different. In 8 weeks after supplementation obese participants had the lowest IgG levels than overweight or normal subjects. The proportion of all types of side effects on the second dose was significantly diminished compared with the first dose in the intervention group.
Conclusion: Supplementation of 600 IU of vitamin D3 can reduce post-vaccination side effects and increase IgG levels in participants who received BioNTech, Pfizer vaccine.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
